EC Dental Science

Research Article Volume 17 Issue 11 - 2018

Overexpression of Lentiviral Vector-Mediated Human BMP2 Gene in Mesenchymal Dental Pulp Stem Cells (DPSCs): An In Vitro Study

Elham Poonaki1, Hossein Bannazadeh Baghi2,3, Marziyeh Aghazadeh4*

1Department of Biotechnology, Islamic Azad University, Damghan, Iran
2Department of Microbiology at Tabriz University of Medical Sciences, Iran
3Department of Virology, Parasitology and Immunology at Ghent University, Belgium
4Assistant Professor of Oral Medicine, Department of Tabriz Dental Faculty, Tabriz, Iran

*Corresponding Author: Marziyeh Aghazadeh, Assistant Professor of Oral Medicine, Department of Tabriz Dental Faculty, Tabriz, Iran.
Received: July 03, 2018; Published: October 31, 2018



Background: Cell based gene therapy is an efficient technique for the cure of inherited diseases as well as for tissue engineering. Hu man bone morphogenetic protein 2 (hBMP2) has been shown to play a significant role in regulating the odontogenic differentiation of dental tissue-derived stem cells. However, there have been few studies on the effects of the BMP2 gene on the proliferation and odontogenic differentiation of human dental pulp stem cells (hDPSCs).

Methods: This study evaluates the overexpression of BMP2 gene transfected in DPSCs infected by lentivirus. DPSCs were transduced with a lentiviral vector to the secretion of BMP2 along with green fluorescent proteins (GFP). The transduced cells were analysed for BMP2 secretion with RT PCR.

Results: Almost 70% of hDPSCs could express GFP marker following transduction. Graphical analysis and GFP assay confirmed that the BMP2 expression level in transduced DPSCs was ten times more than native DPSCs.

Conclusions: DPSCs could be considered as a promising source for tissue engineering. Moreover, lentiviral-mediated BMP2 gene transfection in DPSCs could enhance the osteogenesis or odontogenesis capacity of these cells.

keywords:Bone Morphogenetic Protein (BMP2); Dental Pulp Stem Cells (DPSCs); Lentiviral Vector

  1. Kaur S., et al. “Tissue engineering and its future perspective in therapeutic medicine-A brief review”. Journal of Advanced Medical and Dental Sciences Research4 (2016): 159.
  2. Oryan A., et al. “Bone regenerative medicine: classic options, novel strategies, and future directions”. Journal of Orthopaedic Surgery and Research1 (2014): 18.
  3. Ozdemir T., et al. “Osteoinductive biomaterial geometries for bone regenerative engineering”. Current Pharmaceutical Design19 (2013): 3446-3455.
  4. M Murray PE., et al. “Regenerative endodontics: a review of current status and a call for action”. Journal of Endodontics4 (2007): 377-390.
  5. Jimi E., et al. “The current and future therapies of bone regeneration to repair bone defects”. International Journal of Dentistry (2012): 148261.
  6. Tonelli P., et al. “Bone regeneration in dentistry”. Clinical Cases in Mineral and Bone Metabolism3 (2011): 24-28.
  7. Sheikh Z., et al. “Bone replacement materials and techniques used for achieving vertical alveolar bone augmentation”. Materials6 (2015): 2953-2993.
  8. Bleich NK., et al. “Gene therapy approaches to regenerating bone”. Advanced Drug Delivery Reviews12 (2012): 1320-1330.
  9. Balmayor ER and van Griensven M. “Gene therapy for bone engineering”. Frontiers in Bioengineering and Biotechnology 3 (2015): 9.
  10. Evans CH. “Gene delivery to bone”. Advanced Drug Delivery Reviews12 (2012): 1331-1340.
  11. Jimi E., et al. “Molecular mechanisms of BMP-induced bone formation: cross-talk between BMP and NF-κB signaling pathways in osteoblastogenesis”. Japanese Dental Science Review1 (2010): 33-42.
  12. Xiao YT., et al. “Bone morphogenetic protein”. Biochemical and Biophysical Research Communications3 (2007): 550-553.
  13. Bragdon B., et al. “Bone morphogenetic proteins: a critical review”. Cellular Signalling4 (2011): 609-620.
  14. Carreira AC., et al. “Bone morphogenetic proteins: Facts, challenges, and future perspectives”. Journal of Dental Research4 (2014): 335-345.
  15. Skogh AC and Engstrand T. “Bone morphogenetic proteins in cranial reconstructions: clinical evaluation of heparin-chitosan as a carrier for BMP-2”. Plastic and Reconstructive Surgery6 (2009): 192e-193e.
  16. Chenard KE., et al. “Bone morphogenetic proteins in craniofacial surgery: current techniques, clinical experiences, and the future of personalized stem cell therapy”. Journal of Biomedicine and Biotechnology (2012): 601549.
  17. Argintar E., et al. “Bone morphogenetic proteins in orthopaedic trauma surgery”. Injury8 (2011): 730-734.
  18. Rao SM., et al. “Bone morphogenetic proteins: periodontal regeneration”. North American Journal of Medical Sciences3 (2013): 161-168.
  19. Carreira AC., et al. “Bone morphogenetic proteins: structure, biological function and therapeutic applications”. Archives of Biochemistry and Biophysics 561 (2014): 64-73.
  20. Granjeiro JM., et al. “Bone morphogenetic proteins: from structure to clinical use”. Brazilian Journal of Medical and Biological Research10 (2005): 1463-1473.
  21. Myllylä RM., et al. “Bone morphogenetic proteins 4 and 2/7 induce osteogenic differentiation of mouse skin derived fibroblast and dermal papilla cells”. Cell and Tissue Research2 (2014): 463-470.
  22. Zhang X., et al. “The roles of bone morphogenetic proteins and their signaling in the osteogenesis of adipose-derived stem cells”. Tissue Engineering Part B: Reviews1 (2013): 84-92.
  23. Ducy P and Karsenty G. “The family of bone morphogenetic proteins”. Kidney International6 (2000): 2207-2214.
  24. Huse K., et al. “Role of Smad proteins in resistance to BMP-induced growth inhibition in B-cell lymphoma”. PLoS One10 (2012): e46117.
  25. Wang RN., et al. “Bone Morphogenetic Protein (BMP) signaling in development and human diseases”. Genes and Diseases1 (2014): 87-105.
  26. Yamaguchi A., et al. “Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro”. The Journal of Cell Biology3 (1991): 681-687.
  27. Cheng H., et al. “Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs)”. Journal of Bone and Joint Surgery8A (2003): 1544-1552.
  28. Jung UW., et al. “The efficacy of BMP‐2 preloaded on bone substitute or hydrogel for bone regeneration at peri‐implant defects in dogs”. Clinical Oral Implants Research12 (2015): 1456-1465.
  29. Kim SE., et al. “The effect of immobilization of heparin and bone morphogenic protein-2 (BMP-2) to titanium surfaces on inflammation and osteoblast function”. Biomaterials2 (2011): 366-373.
  30. Yang W., et al. “Bmp2 is required for odontoblast differentiation and pulp vasculogenesis”. Journal of Dental Research1 (2012): 58-64.
  31. Wang Y., et al. “BMP activity is required for tooth development from the lamina to bud stage”. Journal of Dental Research7 (2012): 690-695.
  32. Rakian A., et al. “Bone morphogenetic protein-2 gene controls tooth root development in coordination with formation of the periodontium”. International Journal of Oral Science2 (2013): 75-84.
  33. Smith DM., et al. “Bone morphogenetic protein 2 therapy for craniofacial surgery”. Journal of Craniofacial Surgery5 (2008): 1244- 1259.
  34. Gene Therapy Clinical Trials Worldwide (2010).
  35. Li SD and Huang L. “Non-viral is superior to viral gene delivery”. Journal of Controlled Release 3 (2007): 181-183.
  36. Malik P., et al. “Successful Correction of the Human Cooley’s Anemia β‐Thalassemia Major Phenotype Using a Lentiviral Vector Flanked by the Chicken Hypersensitive Site 4 Chromatin Insulator”. Annals of the New York Academy of Sciences 1 (2005): 238-249.
  37. Brown BD., et al. “A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice”. Blood13 (2007): 4144-4152.
  38. Bianco CL., et al. “Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an α-synuclein rat model of Parkinson’s disease”. Proceedings of the National Academy of Sciences of the United States of America 50 (2004): 17510-17515.
  39. Azzouz Mimoun., et al. “Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy”. The Journal of Clinical Investigation 12 (2004): 1726-1731.
  40. Anson DS. “The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery”. Genetic Vaccines and Therapy1 (2004): 9.
  41. Bushman FD. “Retroviral integration and human gene therapy”. The Journal of Clinical Investigation 8 (2007): 2083-2086.
  42. Martin-Rendon E., et al. “Lentiviral vectors for the treatment of neurodegenerative diseases”. Current Opinion in Molecular Therapeutics 5 (2001): 476-481.
  43. Goss JR., et al. “Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion”. Gene Therapy 7 (2001): 551-556.
  44. Lachmann RH and Efstathiou S. “The use of herpes simplex virus-based vectors for gene delivery to the nervous system”. Molecular Medicine Today 9 (1997): 404-411.
  45. Damda A., et al. “Tissue engineering in endodontics”.
  46. Patel DM., et al. “Therapeutic potential of mesenchymal stem cells in regenerative medicine”. Stem Cells International (2013): 496218.
  47. R Marx RE. “Platelet-rich plasma (PRP): what is PRP and what is not PRP?” Implant Dentistry 4 (2001): 225-228.
  48. Dominici ML., et al. “Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement”. Cytotherapy4 (2006): 315-317.
  49. Huang GJ., et al. “Mesenchymal stem cells derived from dental tissues vs. those from other sources: their biology and role in regenerative medicine”. Journal of Dental Research 9 (2009): 792-806.
  50. Bansal R and Jain A. “Current overview on dental stem cells applications in regenerative dentistry”. Journal of Natural Science, Biology, and Medicine 1 (2015): 29-34.
  51. Zhang W., et al. “Proliferation and odontogenic differentiation of BMP2 gene transfected stem cells from human tooth apical papilla: An in vitro study”. International Journal of Molecular Medicine 4 (2014): 1004-1012.
  52. Samiei M., et al. “Isolation and Characterization of Dental Pulp Stem Cells from Primary and Permanent Teeth”. Journal of American Science 12 (2013): 153-157.
  53. Dalton AC and Barton WA. “Over‐expression of secreted proteins from mammalian cell lines”. Protein Science 5 (2014): 517-525.
  54. Barde I., et al. “Production and titration of lentiviral vectors”. Current Protocols in Neuroscience 23 (2010): 4-21.
  55. Zufferey R and Trono D. “Production of High‐Titer Lentiviral Vectors”. Current Protocols in Human Genetics1 (2002).
  56. Salmon P and Trono D. “Production and titration of lentiviral vectors”. Current Protocols in Human Genetics 24 (2007): 12.
  57. Ylä-Herttuala S and Alitalo K. “Gene transfer as a tool to induce therapeutic vascular growth”. Nature Medicine 6 (2003): 694-701.
  58. Yamaguchi A., et al. “Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro”. The Journal of Cell Biology3 (1991): 681-687.
  59. Rutherford RB. “BMP‐7 gene transfer to inflamed ferret dental pulps”. European Journal of Oral Sciences 6 (2001): 422-424.
  60. Nakashima M., et al. “Induction of reparative dentin formation by ultrasound-mediated gene delivery of growth/differentiation factor 11”. Human Gene Therapy 6 (2003): 591-597.
  61. Nakashima M., et al. “Stimulation of reparative dentin formation by ex vivo gene therapy using dental pulp stem cells electro transfected with growth/differentiation factor 11 (Gdf11)”. Human Gene Therapy 11 (2004): 1045-1053.
  62. Yang X., et al. “Mineralized tissue formation by BMP2-transfected pulp stem cells”. Journal of Dental Research11 (2009): 1020-1025.
  63. Tatullo M., et al. “Dental pulp stem cells: function, isolation and applications in regenerative medicine”. Journal of Tissue Engineering and Regenerative Medicine 11 (2015): 1205-1216.
  64. Turgeman G., et al. “Engineered human mesenchymal stem cells: a novel platform for skeletal cell mediated gene therapy”. The Journal of Gene Medicine 3 (2001): 240-251.
  65. Stathopulos PB. “Taking the good out of the bad: lentiviral-based gene therapy of the hemoglobinopathies”. Biotechnology Advances 6 (2003): 513-526.
  66. Salehi R., et al. “Bioengineering of dental pulp stem cells in a microporous PNIPAAm-PLGA scaffold”. International Journal of Polymeric Materials and Polymeric Biomaterials 15 (2014): 767-776.
  67. Samiei M., et al. “Osteogenic/odontogenic bioengineering with co-administration of simvastatin and hydroxyapatite on poly caprolactone based nanofibrous scaffold”. Advanced Pharmaceutical Bulletin 3 (2016): 353-365.
  68. Zijah V., et al. “Towards optimization of odonto/osteogenic bioengineering: in vitro comparison of simvastatin, sodium fluoride, melanocyte-stimulating hormone”. In Vitro Cellular and Developmental Biology-Animal 6 (2017): 502-512.
  69. Aghazadeh M., et al. “Towards osteogenic bioengineering of dental pulp stem induced by sodium fluoride on hydroxyapatite based biodegradable polymeric scaffold”. Fibers and Polymers 8 (2017): 1468-1477.

M Suchitra., et al. “Overexpression of Lentiviral Vector-Mediated Human BMP2 Gene in Mesenchymal Dental Pulp Stem Cells (DPSCs): An In Vitro Study ”.”. EC Dental Science 17.11 (2018): 01-11.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net